Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early secukinumab versus standard treat-to-target care in newly diagnosed psoriatic arthritis
NL-OMON55356Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab, methotrexate, 5-aminosalicylic acid + sulphasalazine and apremilast in psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Primary endpoint: ACR50 response at 6 months. Started Dec 2019; status: completed.
02
Drugs
secukinumabmethotrexate5-aminosalicylic acid + sulphasalazineapremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON55356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55356.